linjc16/ctgov huggingface dataset:
Renal Failure Following Lung Transplantation in Cystic Fibrosis Patients

Study Overview
=================
Brief Summary
-----------------
With this retrospective observational cohort study, we performed a longitudinal assessment of the renal function of the adult CF patients who underwent LUTX, aiming 1) to describe possible risk factors associated with perioperative AKI and 2) to describe AKI short and long term effects on clinical outcomes.

Detailed Description
-----------------
This study is a retrospective analysis of prospectively collected data from medical records of all consecutive CF patients who underwent LUTX at our Institution from January 2013 to December 2018.

Official Title
-----------------
Perioperative Acute Kidney Injury in Patients With Cystic Fibrosis Undergoing Lung Transplantation: a Retrospective Analysis

Conditions
-----------------
Cystic Fibrosis

Intervention / Treatment
-----------------
* Procedure: Lung Transplantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All patients with CF who underwent LUTX during the study period were considered. Exclusion Criteria: single LUTX re-transplantation missing medical records; age < 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Lung Transplantation|Double lung transplant|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Acute Kidney Injury | AKI stage 1, stage 2, and stage 3 whether a 1.5-1.9 times, 2-2.9 times, and >3 times increase from the preoperative creatinine was measured, respectively. Following KIDGO criteria | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Survival | Death at follow-up | Until May 31 2021 |
Efficacy of Hemostasis by Soft Coagulation Using Endoscopic Hemostatic Forceps for Acute Peptic Ulcer Bleeding

Study Overview
=================
Brief Summary
-----------------
Endoscopic high-frequency soft coagulation is available for the management of bleeding or nonbleeding visible vessels during endoscopic submucosal dissection. However, its efficacy on peptic ulcer bleeding has not been elucidated so far. The aim of this study was to evaluate the efficacy of hemostasis with soft coagulation using hemostatic forceps by comparing it with argon plasma coagulation (APC) in a prospective, randomized trial.

Official Title
-----------------
Efficacy of Hemostasis by Soft Coagulation Using Endoscopic Hemostatic Forceps in Comparison With Argon Plasma Coagulation for Acute Peptic Ulcer Bleeding

Conditions
-----------------
Active Peptic Ulcer Disease/GI Bleeding

Intervention / Treatment
-----------------
* Device: epinephrine injection plus soft coagulation using hemostatic forceps
* Device: epinephrine injection plus argon plasma coagulation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age greater than 18 years peptic ulcer with stigmata of recent hemorrhage Exclusion Criteria: malignant ulcer previous gastric surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: APC group<br>epinephrine injection plus argon plasma coagulation | Device: epinephrine injection plus argon plasma coagulation<br> <br> |
| Active Comparator: Forceps group<br>epinephrine injection plus soft coagulation using hemostatic forceps | Device: epinephrine injection plus soft coagulation using hemostatic forceps<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence of bleeding within four weeks after initial hemostasis |  | up to 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| initial hemostasis rate |  | up to 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
peptic ulcer bleeding, hemostatic forceps, soft coagulation, argon plasma coagulation
Vitamin D Supplementation for the Prevention of Acute Respiratory Tract Infections

Study Overview
=================
Brief Summary
-----------------
The investigators earlier clinical study in 754 young Finnish men demonstrated a significant negative association of serum 25-OHD concentration with acute respiratory tract infections. The present study aimed to determine whether vitamin D supplementation may decrease the incidence of acute respiratory tract infections.

Detailed Description
-----------------
Subjects comprised 164 male conscripts at a military base in Finland. Half of the participants were randomly allocated to receive 400 IU vitamin D daily and half received placebo from October through March. Serum vitamin D and plasma parathyroid hormone concentrations were determined. Subjects were followed for 6 months and the primary outcome was the number of days absent from duty due to ARTI.

Official Title
-----------------
Vitamin D Supplementation for the Prevention of Acute Respiratory Tract Infections; a Randomized Double-blinded Trial in Young Finnish Men

Conditions
-----------------
Respiratory Tract Infections

Intervention / Treatment
-----------------
* Dietary Supplement: vitamin D
* Dietary Supplement: placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Exclusion Criteria: Use vitamin D
Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: vitamin D<br> | Dietary Supplement: vitamin D<br>* vitamin D3 400 IU daily<br>* Other names: Minisun;|
| Placebo Comparator: placebo<br> | Dietary Supplement: placebo<br>* placebo<br>* Other names: Pharmia, Finland;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of days absent from duty due to respiratory tract infection |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The proportion of men remaining healthy throughout the 6-month study period |  | 6 months | 
| The number needed to treat calculated from the proportion of men without any days absent from duty |  | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vitamin D, infection, Vitamin D for the prevention of respiratory tract infections
Effect of Ondansetron for Withdrawal Symptoms

Study Overview
=================
Brief Summary
-----------------
We hope to determine whether Ondansetron, an anti-nausea medication, works to help relieve withdrawal symptoms experienced while the patient is being weaned off opioid medications. This medication has shown anecdotal evidence of being affective for the treatment of withdrawal symptoms and we hope to determine whether this is affective.

Official Title
-----------------
Effect of Ondansetron for Withdrawal Symptoms

Conditions
-----------------
Substance Withdrawal Syndrome

Intervention / Treatment
-----------------
* Drug: Ondansetron and Placebo crossover


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:-Over 18 years of age No medical contraindications to medication Able to fulfill research procedures Exclusion Criteria:-Subjects who are unable to respond to our questionnaires or to stimuli as required by the experimental protocol will be excluded. Subjects will be excluded if they have a history of significant psychiatric disorders that would prevent them from engaging in a treatment program. Participating in other studies that would interfere with the procedures in this study Known or apparent pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Placebo - sugar pill<br>Placebo - sugar pill | Drug: Ondansetron and Placebo crossover<br> <br> |
| Experimental: Ondansetron<br>Ondansetron | Drug: Ondansetron and Placebo crossover<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Withdrawal Symptoms With Placebo and With Ondansetron | Subjective Opioid Withdrawal Scale: Participants were asked to rate, from 0 to 4, their experience of 15 withdrawal symptoms. Scores for each participant were derived from the sum of their withdrawal symptoms score (minimum:0, maximum: 60). A higher score indicates more symptoms experienced and/or at a greater degree of severity. | Baseline, 1 hour post dose Placebo, 1 hour post dose Ondansetron |
Necrotizing External Otitis : Study in a Regional Bone and Joint Infection Reference Center

Study Overview
=================
Brief Summary
-----------------
The malignant external otitis is a rare disease which arises more frequently at the elderly and the diabetics patients. To our knowledge, there are few data and it is not wellc known byclinicians. Nevertheless it exposes to neurological complications potentially serious and crippling.

Official Title
-----------------
Necrotizing External Otitis : Study in a Regional Bone and Joint Infection

Conditions
-----------------
Bone and Joint Infection

Intervention / Treatment
-----------------
* Other: necrotizing external otitis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients having had necrotizing external otitis and managed at the Lyon Bone and joint infection refence Center Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 95 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Necrotizing external otitis<br>description of necrotizing external otitis | Other: necrotizing external otitis<br>* description of necrotizing external otitis<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of necrotizing external otitis | description of necrotizing external otitis: patients, profile of the bacterium, medical and chirurgical treatment, rate | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of Treatment Failure | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin. Analyse of risk factor. | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | 
| Duration of antibiotics | Description of the strategies of antibiotic treatments used (double-agent therapy, monotherapy, duration) | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
otitis
The Assessment of Microcirculation in Brachial Plexus Block Using Perfusion Index and Capillary Filling Time

Study Overview
=================
Brief Summary
-----------------
The aim of the present study is to assess the effects of brachial plexus block on microcirculation using pefusion index and capillary filling time.

Detailed Description
-----------------
Microcirculation is very crucial to evaluate the organ function those working properly in human body. The aim of the present study is to assess the effects of brachial plexus block on microcirculation using pefusion index and capillary filling time. A total of 50 patients whose planned to underwent surgery are performed brachial plexus block using ultrasound, and pefusion index, heart rate, blood pressure, capillary filling time are measured at 0, 10th and 20th minutes interval and at postoperative 24th hours. All measures will be recorded.

Official Title
-----------------
The Assessment of Microcirculation in Brachial Plexus Block Using Perfusion Index and Capillary Filling Time

Conditions
-----------------
Circulatory; Change

Intervention / Treatment
-----------------
* Device: pefusion index measurement


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists score of I and III ages between 18 and 70 upper extremity surgery Exclusion Criteria: not to participate in the study reject to perform the intervention infection in injection cite allergy to local anesthetics peripherical vasculary diseases psychiatric diseases coagulation anomalies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: pefusion index measurement|perfusion index measurement using massimo radical 7 device|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| perfusion index |  | five times in one year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| capillary filing time |  | five times in one year | 
| heart rate |  | five times in one year | 
| blood pressure |  | five times in one year | 
| oxygen saturation |  | five times in one year |
A NEW SCORING SYSTEM FOR PREDICTION OF PDA

Study Overview
=================
Brief Summary
-----------------
Patent ductus arteriosus (PDA) is an important morbidity of that the diagnosis and treatment is controversy in premature infants. A number of scoring systems have been developed, including the findings of echocardiography on the diagnosis and treatment of PDA. This study aimed to develop a new clinical scoring system that will enable the rapid, standard and noninvasive evaluation of hemodynamically significant PDA earlier, without relying on echocardiographic findings in premature babies with extremely low birth weight, and to determine the role of this scoring system in early diagnosis and treatment.

Detailed Description
-----------------
This study aimed to develop a new clinical scoring system that will enable the rapid, standard and noninvasive evaluation of hemodynamically significant PDA earlier, without relying on echocardiographic findings in premature babies with extremely low birth weight, and to determine the role of this scoring system in early diagnosis and treatment.

Official Title
-----------------
Can a New Scoring System Predict Hemodynamically Significant PDA Diagnosis and Treatment Requirement for Extremely Preterm Newborns Earlier

Conditions
-----------------
Patent Ductus Arteriosus, Prematurity; Extreme

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: informed consent obtained from parents extremely preterm infants infants born before 28 gestational week Exclusion Criteria: lack of informed consent chromosomal abnormality cardiovascular abnormality

Ages Eligible for Study
-----------------
Maximum Age: 15 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of Participants with Patent Ductus Arteriosus | number of participants who diagnosed for hemodynamically significant PDA and had an elevated score of the newly developed system by us. | 7 days |
Predictors of De-novo Development of Obstructive Sleep Apnea in Pregnancy

Study Overview
=================
Brief Summary
-----------------
This study seeks to understand the physical, physiologic and biologic features that predispose a woman to the development of obstructive sleep apnea once they are exposed to the cardiopulmonary and metabolic physiological changes of pregnancy. Knowing these specific predictive factors can help identify a population at risk and guide clinicians to develop suitable targeting screening strategies.

Detailed Description
-----------------
Patients will be recruited from multiple community and hospital-based practices that care for pregnant women. Subjects will have: measurements of body composition anthropometric measures sleep and mood questionnaires Home sleep studies blood testing for biological markers salivary testing for hormonal markers pulmonary function tests and upper airway patency measurements Women without sleep apnea at enrollment will then be followed longitudinally for the development of obstructive sleep apnea during pregnancy with repeat assessment during their third trimester. Women diagnosed with sleep apnea at enrollment will have no further assessment in late pregnancy. Monetary incentives will also be issued at data collection points. Subjects will receive small gift incentives such as baby-related items.

Official Title
-----------------
Predictors of De-novo Development of Obstructive Sleep Apnea in Pregnancy

Conditions
-----------------
Pregnancy, Obstructive Sleep Apnea, Obesity, Sleep

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: <13 completed weeks of gestation BMI >30 kg/m2 at recruitment >18 years of age Ability to give informed consent Exclusion Criteria: Unable to meet inclusion criteria Twin pregnancies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Characteristics of participants who develop obstructive sleep apnea defined as an apnea hypopnea index >5 events per hour | The study will develop a model of biologic, physiologic and anthropometric measures that predict the development of obstructive sleep apnea apnea later in pregnancy compared to baseline in early pregnancy. | Up to 40 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Obstructive Sleep Apnea, Pregnancy, Obesity, Fluid shifts, Body composition, Sleep
Cyanobacteria Allergy in Lake Kineret

Study Overview
=================
Brief Summary
-----------------
People swimming or surfing in lake Kineret , sometimes complain of nasal stuffiness , sneezing and itching .Typically, it happens during or immediately after contact with the lake's water . The symptoms are compatible with immediate allergic reaction. Previous reports suggested a connection between similar symptoms and contact with different cyanobacteria (living in fresh water lakes). In this study we intend to prove the mechanism of these reactions. To prove the exact allergen that causes allergic rhinitis allergists perform skin tests with different suspected allergens. Likewise, we would like to perform skin tests to different proteins extracted from cyanobacteria collected in lake Kineret.

Official Title
-----------------
Cyanobacteria Allergy in Lake Kineret

Conditions
-----------------
Nasal Stuffiness, Sneezing, Itching

Intervention / Treatment
-----------------
* Procedure: Skin test with sterile extracts of different cyanobacteria


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age above 18 exposed to Lake Keneret water by swiming or sirfing Exclusion Criteria: age under 18 pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Skin test with sterile extracts of different cyanobacteria|Skin test with sterile extracts of different cyanobacteria is performed on the volar aspect of the forearm. Typically, the results are read 15 minutes after performing the test. Test is regarded as positive when wheal of more than 3mm and flare appear within this time frame. Positive test indicates the existence of specific IgE to the extract in on skin mast cells .|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reproducibility of skin test to cyanobacteria |  | Immediately after performing the test (15 minutes) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
allergy, cyanobacteria, sweet water swimming